Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical

Description:

Aarkstore.com announce a new report "Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical" through its vast collection of market research report. – PowerPoint PPT presentation

Number of Views:119

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical


1
Aarkstore.com Lung Cancer Therapeutic
Antibodies Pipeline, Strategies and Clinical
2
Summary
  • This report provides a comprehensive review of 27
    candidate therapeutic antibodies that are being
    evaluated for the treatment of lung cancer
    covering pipeline, disease-targeting strategies
    and clinical findings. These antibodies are
    directed at 17 potential targets. Globally,
    lung cancer is the most common cancer and in 2008
    there were an estimated 1.6 million new cases and
    1.4 million deaths (almost 20 of all cancer
    deaths) caused by this disease. Five-year
    survival rates are also low (15-20) compared to
    other common cancers. In the US, studies have
    shown that lung cancer-care costs (in 2006) were
    the third highest of all cancers, while indirect
    costs (2005) were higher than for any other
    cancer. Patient needs and the high burden of
    lung cancer on society drive the development of
    new therapies. While improvements have been seen
    in diagnosis and treatments (surgery,
    radiotherapy, chemotherapy and targeted drugs),
    new therapies that build on the capabilities of
    existing approaches, are urgently
    requiredToday, developments continue to be made
    in drug treatments for lung cancer in
    chemotherapy, new drug combinations, and targeted
    molecules. In particular, advances are being seen
    in the field of immunotherapy in the development
    of new therapeutic antibodies and therapeutic
    vaccines.

3
Table of Contents
  • Summary1 Lung Cancer1.1 Statistics1.2
    Diagnosis1.3 Lung Cancer Staging1.4 Treatment
    of Lung Cancer1.5 Survival Rates1.6 Cost of
    Lung Cancer1.7 New Developments1.8 This
    ReportReferencesChapter 2 Approved and
    Late-Stage Therapeutic AntibodiesSummary2.1
    Introduction2.2 Overview2.3 (One antibody,
    Approved)2.4 2.6 (Three antibodies, Phase
    3)References

4
More Related Reports
  •   VEGF Inhibition Therapy-Indicating and
    Prognostic Biomarkers, 2011
  •   Biomarkers in Alzheimers Disease, 2011
  •   Alzheimers Disease Autoantibodies, Vaccines
    and Therapeutic Antibodies Pipeline, 2011
  •   Prostate Cancer Vaccines and Therapeutic
    Antibodies Pipeline, 2011
  •   Breast Cancer Vaccines and Therapeutic
    Antibodies Pipeline, 2011
  •   Alzheimers Disease Biomarkers in Cerebrospinal
    Fluid and Blood, 2011
  •   Image-Based Biomarkers in Alzheimers Disease,
    2011
  •   Lung Cancer Vaccines and Therapeutic
    Antibodies Pipeline, Strategies and Clinical

5
For More details
  • http//www.aarkstore.com/reports/Lung-Cancer-Thera
    peutic-Antibodies-Pipeline-Strategies-and-Clinical
    -157142.html
  • Vina
  • Aarkstore.com
  • Contact Marketing team
  • Mob.No.918149852585
  • Email enquiry_at_aarkstore.com
  • URL http//www.aarkstore.com/
  • XML http//www.aarkstore.com/feeds/Biopharmrepor
    ts.xml
About PowerShow.com